UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute-Designated Cancer Centers

The cancer journal (Sudbury, Mass.), 2022-03, Vol.28 (2), p.111-117

2022

Volltextzugriff (PDF)

Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis

BMJ (Online), 2022-06, p.e067745

2022

Volltextzugriff (PDF)

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3709-3714

2008

Volltextzugriff (PDF)

Matching Patients to Accelerate Clinical Trials (MPACT): Enabling Technology for Oncology Clinical Trial Workflow

Studies in health technology and informatics, 2024-01, Vol.310, p.1086

2024

Volltextzugriff (PDF)

Ten‐year follow‐up of a phase 2 study of dose‐intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor‐prognosis, advanced‐stage epithelial ovarian cancer

Cancer, 2010-03, Vol.116 (6), p.1476-1484

2010

Volltextzugriff (PDF)

Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer

Journal of clinical oncology, 2003-12, Vol.21 (23), p.4356-4363

2003

Volltextzugriff (PDF)

A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors

Cancer biology & therapy, 2009-10, Vol.8 (19), p.1800-1805

2009

Volltextzugriff (PDF)

A Phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: Potential efficacy of the combination and demonstration of pharmacokinetic interaction

Clinical cancer research, 2001-06, Vol.7 (6), p.1600-1609

2001

Volltextzugriff (PDF)

An analysis of clinical trials in clinicaltrials.gov to assess the scope of NCI support and inclusion on NCI’s cancer.gov website

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e18029-e18029

2016

Volltextzugriff (PDF)

TEN-YEAR FOLLOW UP OF A PHASE II STUDY OF DOSE-INTENSE PACLITAXEL WITH CISPLATIN AND CYCLOPHOSPHAMIDE AS INITIAL THERAPY FOR POOR-PROGNOSIS ADVANCED-STAGE EPITHELIAL OVARIAN CANCER

Cancer, 2010-03, Vol.116 (6), p.1476-1484

2010

Volltextzugriff (PDF)

Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian Cancer

JNCI : Journal of the National Cancer Institute, 1994-01, Vol.86 (1), p.18-24

1994

Volltextzugriff (PDF)

Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers

Cancer research (Chicago, Ill.), 1996-02, Vol.56 (3), p.569-573

1996

Volltextzugriff (PDF)

Autologous stem-cell transplantation in ovarian cancer: is more better?

Annals of internal medicine, 2000-10, Vol.133 (7), p.555

2000

Volltextzugriff (PDF)

Borderline ovarian tumors

The American journal of medicine, 1996-08, Vol.101 (2), p.217-225

1996

Volltextzugriff (PDF)

Phase I clinical trial of carbetimer

Cancer research (Chicago, Ill.), 1988-09, Vol.48 (18), p.5353-5357

1988

Volltextzugriff (PDF)

Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer

Cancer, 1998-11, Vol.83 (9), p.1980-1988

1998

Volltextzugriff (PDF)

A Phase I/II Study of Dose-Intense Paclitaxel with Cisplatin and Cyclophosphamide as Initial Therapy of Poor-Prognosis Advanced-Stage Epithelial Ovarian Cancer

Gynecologic oncology, 1996-08, Vol.62 (2), p.181-191

1996

Volltextzugriff (PDF)

FUTURE DIRECTIONS WITH TAXANE THERAPY

Hematology/oncology clinics of North America, 1999-02, Vol.13 (1), p.21-41

1999

Volltextzugriff (PDF)

Incapacitating Autonomic Neuropathy Precipitated by Taxol

Gynecologic oncology, 1993-11, Vol.51 (2), p.277-280

1993

Volltextzugriff (PDF)

Anthracycline analogs: the past, present, and future

Cancer chemotherapy and pharmacology, 1986-01, Vol.18 (3), p.185-197

1986

Volltextzugriff (PDF)

Age does not influence taxol dose intensity in recurrent carcinoma of the ovary

Cancer, 1993-01, Vol.71 (S2), p.594-600

1993

Volltextzugriff (PDF)

Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction

Clinical cancer research, 1995-08, Vol.1 (8), p.797-803

1995

Volltextzugriff (PDF)

A Phase I Study of Paclitaxel and Cyclophosphamide in Recurrent Adenocarcinoma of the Ovary

Gynecologic oncology, 1996-06, Vol.61 (3), p.349-353

1996

Volltextzugriff (PDF)

Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy

Blood, 1994-03, Vol.83 (5), p.1188-1192

1994

Volltextzugriff (PDF)

Cutaneous manifestations of taxol® therapy

Investigational new drugs, 1995-01, Vol.13 (3), p.261-263

1995

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

Humans
(27)
Female
(25)
Life Sciences & Biomedicine
(25)
Science & Technology
(25)
Biological And Medical Sciences
(22)
Medical Sciences
(22)
Oncology
(21)
Middle Aged
(20)
Aged
(19)
Adult
(17)
Pharmacology. Drug Treatments
(16)
Antineoplastic Agents
(14)
Ovarian Neoplasms - Drug Therapy
(14)
Chemotherapy
(12)
Male
(9)
Treatment Outcome
(9)
Drug Administration Schedule
(8)
Neoplasms - Drug Therapy
(8)
Paclitaxel - Administration & Dosage
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute-Designated Cancer Centers

Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

Matching Patients to Accelerate Clinical Trials (MPACT): Enabling Technology for Oncology Clinical Trial Workflow

Ten‐year follow‐up of a phase 2 study of dose‐intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor‐prognosis, advanced‐stage epithelial ovarian cancer

Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer

A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors

A Phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: Potential efficacy of the combination and demonstration of pharmacokinetic interaction

An analysis of clinical trials in clinicaltrials.gov to assess the scope of NCI support and inclusion on NCI’s cancer.gov website

TEN-YEAR FOLLOW UP OF A PHASE II STUDY OF DOSE-INTENSE PACLITAXEL WITH CISPLATIN AND CYCLOPHOSPHAMIDE AS INITIAL THERAPY FOR POOR-PROGNOSIS ADVANCED-STAGE EPITHELIAL OVARIAN CANCER

Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers

Autologous stem-cell transplantation in ovarian cancer: is more better?

Borderline ovarian tumors

Phase I clinical trial of carbetimer

Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer

A Phase I/II Study of Dose-Intense Paclitaxel with Cisplatin and Cyclophosphamide as Initial Therapy of Poor-Prognosis Advanced-Stage Epithelial Ovarian Cancer

FUTURE DIRECTIONS WITH TAXANE THERAPY

Incapacitating Autonomic Neuropathy Precipitated by Taxol

Anthracycline analogs: the past, present, and future

Age does not influence taxol dose intensity in recurrent carcinoma of the ovary

Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction

A Phase I Study of Paclitaxel and Cyclophosphamide in Recurrent Adenocarcinoma of the Ovary

Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy

Cutaneous manifestations of taxol® therapy

Suchergebnisse filtern